论文部分内容阅读
[目的]探讨乳腺癌患者治疗前后血浆D-二聚体水平变化及其临床意义。[方法]测定95例乳腺癌患者及80例乳腺良性肿瘤患者治疗前后的血浆D-二聚体水平。[结果]治疗前乳腺癌组的血浆D-二聚体水平高于乳腺良性肿瘤组,差异有显著统计学意义(P<0.01);治疗前有淋巴结转移乳腺癌患者血浆D-二聚体水平高于无淋巴结转移患者(P<0.05),临床Ⅰ~Ⅱ期患者血浆D-二聚体水平低于Ⅲ期患者(P<0.05)。乳腺癌患者治疗后血浆D-二聚体水平低于治疗前(P<0.05)。[结论]血浆D-二聚体水平检测在乳腺癌患者的病情评估、疗效观察、预后判断等方面具有重要的临床应用价值。
[Objective] To investigate the change of plasma D-dimer level in patients with breast cancer before and after treatment and its clinical significance. [Method] The levels of plasma D-dimer in 95 patients with breast cancer and 80 patients with benign breast tumor before and after treatment were measured. [Results] The level of plasma D-dimer in pre-treatment group was significantly higher than that in benign breast neoplasm group (P <0.01). The level of plasma D-dimer in patients with lymph node metastasis before treatment (P <0.05). The level of plasma D-dimer in stage Ⅰ-Ⅱ patients was lower than that in stage Ⅲ patients (P <0.05). Plasma D-dimer levels after treatment in breast cancer patients were lower than before treatment (P <0.05). [Conclusion] The detection of plasma D-dimer level has important clinical value in breast cancer patients’ condition evaluation, curative effect observation and prognosis judgment.